Loading...
Market
What will be the outcome of the first phase of PBGENE-HBV trial by end of 2025?
2
Resolution / Starting Odds
Successful with no adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful • 25%
Trial halted due to safety concerns • 25%
Official trial results published by Precision BioSciences
Story
Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B
Oct 24, 2024, 12:51 PM
Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Significant reduction in HIV levels (over 1000-fold) • 25%
Moderate reduction in HIV levels (100-1000 fold) • 25%
Minimal reduction in HIV levels (less than 100 fold) • 25%
No significant reduction in HIV levels • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Proven integration in humans • 25%
No integration found • 25%
Inconclusive results • 25%
Study not completed • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
